Electrocore LLC

NASDAQ ECOR

Data sourced from iex and EODHD
Download Data

Electrocore LLC Working Capital to Current Liabilities Ratio 2 year CAGR for the quarter ending March 31, 2024: -71.10%

Electrocore LLC Working Capital to Current Liabilities Ratio 2 year CAGR is -71.10% for the quarter ending March 31, 2024, a -89.89% change year over year. The working capital to current liabilities ratio measures the proportion of working capital to current liabilities. It is calculated by dividing the difference between current assets and current liabilities by current liabilities. This ratio indicates the company's ability to cover its current liabilities with its working capital. A higher ratio suggests a healthier liquidity position and better ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Electrocore LLC Working Capital to Current Liabilities Ratio for the quarter ending March 31, 2023 was 1.63, a -72.57% change year over year.
  • Electrocore LLC Working Capital to Current Liabilities Ratio for the quarter ending March 31, 2022 was 5.94, a 42.68% change year over year.
  • Electrocore LLC Working Capital to Current Liabilities Ratio for the quarter ending March 31, 2021 was 4.16, a 204.38% change year over year.
  • Electrocore LLC Working Capital to Current Liabilities Ratio for the quarter ending March 31, 2020 was 1.37, a -85.96% change year over year.
NASDAQ: ECOR

Electrocore LLC

CEO Mr. Daniel S. Goldberger
IPO Date June 22, 2018
Location United States
Headquarters 200 Forge Way, Rockaway, NJ, United States, 07866
Employees 68
Sector Healthcare
Industry Medical devices
Description

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

StockViz Staff

September 19, 2024

Any question? Send us an email